Business
Red Light Holland : Expands New Zealand Partnership with Allu Therapeutics to Advance Access to Filament Health’s GMP-Compliant PEX010 Botanical Psilocybin Drug Candidate
Red Light Holland : Expands New Zealand Partnership with Allu Therapeutics to Advance Access to Filament Health’s GMP-Compliant PEX010 Botanical Psilocybin
About this update from Red Light Holland Corp
[{"type":"text","content":"\n The expanded agreement adds Filament Health, a wholly owned subsidiary of Red Light Holland, as a supplying affiliate and introduces a GMP-compliant standardized microdose format of PEX010 supported by long-term stability and safety data.\n \n Toronto, Ontario--(Newsfile Corp. - May 25, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (\"Red Light Holland\", \"Red Light\", or the \"Company\"), is an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. (\"Filament\"), the Company has expanded its pharmaceutical-grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development and Filament's patented botanical drug candidate, PEX010. The Company is pleased to announce it has signed an addendum (the \"Addendum\") to its existing supply agreement with Allu Therapeutics Limited (\"Allu\"), expanding the relationship in New Zealand to include the supply of Filament Health's GMP-compliant PEX010 botanical psilocybin drug candidate.\n \n \n The Addendum formally adds Filament Health as a supplying affiliate under the agreement and expands available PEX010 formats to include a standardized microdose format of PEX010. To the Company's knowledge, this represents the first GMP-compliant standardized microdose format of a botanical psilocybin drug candidate, differentiating it from synthetic formulations and non-standardized products currently available in the market.\n \n \n The expanded agreement reflects Red Light's ongoing commitment to advancing access to GMP-compliant PEX010 through a quality-controlled and regulatory-conscious supply framework designed to support research initiatives and regulated access pathways over time. New Zealand's evolving regulatory framework, which permits authorized psychiatrists to prescribe psilocybin to treatment-resistant patients on a case-by-case basis, represents an important step toward expanding patient access and supporting responsible medicinal use initiatives within the region.\n \n \n \"This expanded agreement with Allu reflects the strategic value of the Filament acquisition,\" said Todd Shapiro, CEO and Director of Red Light. \"By introducing Filament Health's GMP-compliant PEX010 into this partnership,...